Stockrabit · Analysts
Questions across 2 calls

Udit Bokaria

Catamaran

Anthem Biosciences Limited

Anthem Biosciences Limited CC-May26.pdf · 2026-05-20
Thanks for the opportunity. Just wanted to understand a few of the commercial molecules, which we were working with biotech companies were acquired by large pharma. You had mentioned in the past that they are yet to be launched commercially by the big pharma , because they were still doing some assessment, right . So, when do we expect that to be launched? That's the first question. Secondly, if you can share what your US biotech partner is talking about now, biotech funding environment, and are you seeing increase in the inquiries?
How should one read from the customer indication when can we expect the ramp-up happening for these products?

Syngene International Limited

Syngene International Limited CC-Jun24.pdf · 2024-07-25
I just wanted to understand if you can share what has been the client response to the new platform? And how should we think about ho w big or how many inquiries can we expect because of this development?
And some of your partnerships, which you had announced last year, like with Cromos or even with ERS Genomics, how has that helped you either win more share with big pharma or attract more number of biotech companies if you can just highlight that.